Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01789476 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

A Phase 2 study of Acute Pain, sponsored by Cara Therapeutics.

Completed
Registry status
Phase 2
Development phase
51
Enrollment target
1
Study location

NCT01789476 is a Phase 2 study of Acute Pain that has completed, run by Cara Therapeutics. The registered enrollment target is 51 participants, below the 267-participant average among 50 other Acute Pain trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01789476, a Phase 2 study of Acute Pain, has completed, sponsored by Cara Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
51 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, randomized, double blind, placebo controlled, parallel group proof of concept study to evaluate the analgesic efficacy as well as the safety, tolerability and pharmacokinetic profile of CR845 in patients with pain following bunionectomy surgery.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG CR845

Study Locations (1)

Utah

  • Jean Brown Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2013-05
Est. Completion 2013-08
Phase Phase 2

Sponsor

Cara Therapeutics

23 total trials

What the Registry Record Tells You About NCT01789476

The ClinicalTrials.gov registry entry for NCT01789476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 50 other Acute Pain trials with a reported enrollment target (81% lower). The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01789476 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT01789476 about?

NCT01789476 is a clinical study titled "A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery". This is a single-center, randomized, double blind, placebo controlled, parallel group proof of concept study to evaluate the analgesic efficacy as well as the safety, tolerability and pharmacokinetic profile of CR845 in patients with pain following bunionectomy surgery.

What is the current status of trial NCT01789476?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2013-05. Estimated completion is 2013-08.

What conditions does trial NCT01789476 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT01789476?

The interventions under investigation include: Placebo (DRUG), CR845 (DRUG).

Who is sponsoring clinical trial NCT01789476?

This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01789476 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.